Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

• Published in: BMC urology Vol. 22; no. 1; p. 204
• Main Authors: Ayoub, Zeina, Khader, Jamal, Bulbul, Muhammad, Khauli, Raja B, Andraos, Therese Y, Shamseddine, Ali, Mukherji, Deborah, Geara, Fady B
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.12.2022; BioMed Central; BMC
• Subjects: Androgen Antagonists - therapeutic use; Androgen deprivation therapy; Androgens; Cancer patients; Cancer therapies; Cardiovascular disease; Care and treatment; Diabetes; Disease-Free Survival; Health aspects; Humans; Immunological tolerance; Male; Medical prognosis; Multivariate analysis; Nadir PSA; Patients; Prostate cancer; Prostate-Specific Antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - radiotherapy; Radiation; Radiation therapy; Radiotherapy; Retrospective Studies; Risk factors; Survival; Prostate cancer; Nadir PSA; Androgen deprivation therapy
• ISSN: 1471-2490; 1471-2490
• DOI: 10.1186/s12894-022-01145-x

A nadir Prostate-Specific Antigen (nPSA) of 0.06 ng/mL has been shown to be a strong independent predictor of biochemical recurrence-free survival (bRFS) in patients with intermediate or high-risk (HR) prostate cancer treated with definitive external beam radiation therapy (RT) and androgen deprivation therapy (ADT). We aimed to examine the association between the duration of ADT and bRFS in HR localized prostate cancer, based on nPSA. Between 1998 and 2015, 204 patients with HR localized prostate cancer were identified. Of them, 157 patients (77.0%) reached the desired nPSA of < 0.06 ng/mL (favorable group), while 47 (23.0%) did not (unfavorable group). Duration of ADT varied among patients depending on physician preference, patient tolerance, and/or compliance. Survival outcomes were calculated using Kaplan-Meier methods and predictors of outcomes using multi-variable cox regression model. In the favorable group, ADT for at least 12 months lead to superior bRFS compared to ≤ 9 months of ADT (P = 0.036). However, no significant difference was seen when examining the value of receiving ADT beyond 12, 18, or 24 months, respectively. On univariate analysis for bRFS, the use of ADT for at least 12 months was significant (P = 0.012) as well as time to nadir PSA (tnPSA), (≤ 6 vs > 6 months); (P = 0.043). The presenting T stage was borderline significant (HR 3.074; 95% CI 0.972-9.719; P = 0.056), while PSA at presentation, Gleason Score and age were not. On multivariate analysis, the use of ADT for 12 months (P = 0.012) and tnPSA (P = 0.037) remained significant. In the unfavorable group, receiving ADT beyond 9 and 12 months was associated with improved bRFS (P = 0.044 and 0.019, respectively). However, beyond 18 months, there was no significant difference. In HR localized prostate cancer patients treated with definitive RT and ADT, the total duration of ADT may be adjusted according to treatment response using nPSA. In patients reaching a nPSA below 0.06 ng/mL, a total of 12 months of ADT may be sufficient, while in those not reaching a nPSA below 0.06 ng/mL, a total duration of 18 months is required.